Ovid Therapeutics
OVID
82 hedge funds and large institutions have $44.4M invested in Ovid Therapeutics in 2024 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 24 increasing their positions, 21 reducing their positions, and 7 closing their positions.
100% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 7
14% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 21
9% more funds holding
Funds holding: 75 → 82 (+7)
1.71% more ownership
Funds ownership: 65.28% → 66.99% (+1.7%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
19% less capital invested
Capital invested by funds: $54.7M → $44.4M (-$10.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.12M |
| 2 |
SCM
Sio Capital Management
New York
|
+$1.12M |
| 3 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$353K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$326K |
| 5 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$104K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
-$860K |
| 2 |
MAP
Madison Avenue Partners
New York
|
-$441K |
| 3 |
BlackRock
New York
|
-$432K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$153K |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$129K |
OVID Hedge Fund Activity: Q4 2024 in Review
82 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q4 2024, worth a combined $44.4M — down 19% from $54.7M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new OVID positions and 7 closed out — a net gain of 7 holders — while 24 added to existing stakes and 21 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $1.12M. The largest seller was Prosight Management, exiting entirely with an estimated $860K sold.
- 82 institutional investors held Ovid Therapeutics (OVID) as of Q4 2024, up from 75 in Q3 2024.
- Funds reported $44.4M of Ovid Therapeutics stock for Q4 2024, down 19% quarter-over-quarter.
- 14 funds opened new Ovid Therapeutics positions in Q4 2024 and 7 closed out, a net change of +7 holders.
- The largest Ovid Therapeutics buyer in Q4 2024 was Adage Capital Partners, an estimated $1.12M added.
- The largest Ovid Therapeutics seller in Q4 2024 was Prosight Management, an estimated $860K sold.
Based on aggregated 13F filings for Q4 2024.